Overview: FDA is Still “Asleep at the Switch”
By Lyn Redwood, RN, MSN, Executive Director
On March 30th of this year, Robert F. Kennedy Jr., and the Children’s Health Defense team met with the Director of the FDA’s Center for Biologics Evaluation and Research (CBER) Dr. Peter Marks, M.D., Ph.D. and his colleagues to discuss the agency’s ongoing refusal to ban thimerosal, a mercury-based preservative, from vaccines in the United States. CBER is the division of the FDA responsible for approving and monitoring the safety of all biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.
At the meeting, we presented a large amount of research showing the toxicity of thimerosal in humans, animals and cellular models, including at levels similar to those resulting from vaccine exposures. We expressed our alarm regarding the total lack of adequate safety testing of thimerosal prior to licensure, especially given its current use in vaccines approved for infants and pregnant women and its worldwide use in millions of vaccines given to children, particularly in developing countries. Dr. Marks promised to look over the studies and seriously consider our concerns.
Here is the correspondence that followed:
April 24, 2017: Lyn Redwood Letter to Peter Marks, FDA [PDF]
July 11, 2017: Peter Marks Letter to Lyn Redwood [PDF]
November 13, 2017: Lyn Redwood Letter to Peter Marks, FDA [PDF][Article]
Sign up for free news and updates from Children’s Health Defense. CHD focuses on legal strategies to defend the health of our children and obtain justice for those injured. We can't do it without your support.